Please login to the form below

Triple negative breast cancer

This page shows the latest Triple negative breast cancer news and features for those working in and with pharma, biotech and healthcare.

Trial failure for bintrafusp alfa casts doubt on GSK/Merck KGaA’s cancer alliance

Despite failing in NSCLC, bintrafusp alfa will continue to be evaluated in a number of additional clinical trials across a range of cancer types. ... Merck. The German pharma company also recently initiated monotherapy studies in triple-negative breast

Latest news

Kite and Oxford BioTherapeutics sign oncology research pact

for the treatment of metastatic triple-negative breast cancer (mTNBC).
Boehringer spends €1.18bn to acquire NBE-Therapeutics

NBE’s lead candidate, NBE-002, is currently in phase 1 clinical studies for triple negative breast cancer and a number of additional solid tumours. ... Merk &Kollegen’s manufacturing site, which is involved in ATMP-based cancer immunology treatments.
Merck strengthens oncology pipeline with $2.75bn VelosBio deal

In October, VelosBio announced that it has initiated a phase 2 clinical trial set to investigate VLS-101 for the treatment of patients with solid tumours, including patients with triple-negative ... breast cancer (TNBC), hormone receptor-positive and/or
Gilead agrees $21bn buyout of Immunomedics

treatment of metastatic triple-negative breast cancer (mTNBC). ... The ADC is also being studied in an ongoing phase 3 trial in third line HR+/HER2-positive breast cancer, and a registrational phase 2 study in bladder cancer.
Merck signs separate agreements with Seattle Genetics for two cancer drugs

As part of this expansive clinical programme, Merck and Seattle Genetics are set to investigate ladiratuzumab vedotin in a number of additional cancer types, including triple-negative breast cancer, hormone ... Tukysa was approved by the US Food and Drug

More from news
Approximately 4 fully matching, plus 67 partially matching documents found.

Latest Intelligence

Cortellis Drugs to Watch in 2020 report

9. Immunomedic’s sacituzumab govitecan initial target market is metastatic triple negative breast cancer in patients who have failed at least two prior therapies. ... It is approved in the US for the treatment of unresectable or metastatic
Deal Watch January 2018

The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer ... that is highly selective for HER2
Deal Watch February 2017

triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. . ... Acquisition - company. 2, 475. Immunomedics/ Seattle Genetics. IMMU-132 (sacituzumab govitecan), an antibody drug
Pharma deals during February 2014

awarded FDA breakthrough therapy status for advanced melanoma last year, and is being studied in 13 clinical trials across more than 30 types of cancer. Financial terms for these deals were ... BATON studies in colorectal cancer and metastatic triple

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

July 2020: diversity and inclusion in clinical trials round-up

The shocking stats surrounding black women and health outcomes. Alarmingly, although black women are overall less likely to develop breast cancer, they’re 40% more likely to die from it compared ... Black women are at higher risk for a type of
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)

cell carcinoma, Merkel cell carcinoma, and triple-negative breast cancer (TNBC) via chest-wall lesions.8. ... 2018; 15(10):599-616. National Cancer Institute. Surveillance, Epidemiology, and End Results Program.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Healthcare Senior Account Manager: Competitive

Commercial Finance Director, Healthcare Marketing Communications...: up to £90K

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

Medical Editor: Competitive

Account Director – Creative Healthcare Communications: Competative

Healthcare Lead Copywriter: Competitive

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Healthcare Account Director: Competitive

PMHub

Add my company

Aurora Healthcare Communications

We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...

Latest intelligence

Patient recruitment and retention 2021 state of play: At COUCH Health, we’ve recently done some social listening to look into the discussions around ‘patient recruitment’ and ‘patient retention’, to see if these conversations have been impacted by the...
The UK has approved the first vaccine for COVID-19. What now?: The authorisation of Pfizer/BioNtech's mRNA vaccine by the MHRA is great news, but no-one has ever tried to roll out a vaccine as rapidly as this one, so we have...
Clinical trials and the diversity principle: If they were ever really hidden, 2020 revealed the expensive-sounding problems limiting diversity in clinical trials. Solutions are overdue....